Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SARS-CoV-2 envelope protein is one of four major structural proteins in the virus, consisting of 75 amino acids forming a single α-helical transmembrane segment and a short cytoplasmic tail featuring a PDZ-binding motif linked to virulence[3][4][9]. It assembles into a pentameric cation channel (viroporin) in the ER-Golgi intermediate compartment (ERGIC) membrane, facilitating ion (notably Na+ and Ca2+) conduction critical for viral assembly, budding, release, and pathogenicity[1][9]. The protein also mediates interactions with viral and host proteins, including cell junction and immune receptors, promoting viral egress and contributing to virulence[7][9]. Inhibitors targeting the envelope protein’s channel activity (e.g., hexamethylene amiloride) are under active investigation as antiviral agents[1][2][9]. The E protein is highly conserved across SARS-CoV-2 variants, and its C-terminal PBM is recognized as a determinant of disease severity[3][4][7][9].
Ion channel inhibition (viroporin inhibition); Interference with protein-protein interactions relevant for viral assembly and virulence (e.g., blocking E-PALS1 interactions)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SARS-CoV-2 envelope protein (E protein).